# 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

> **NCT01640951** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 675 (actual)

## Conditions studied

- Moderate to Severe Chronic Plaque-Type Psoriasis

## Interventions

- **DRUG:** AIN457 150 mg
- **DRUG:** AIN457 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01640951
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-16
- **Primary completion:** 2017-05-04
- **Final completion:** 2017-05-04
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2018-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01640951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01640951, "4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01640951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*